Modern trends in antiplatelet therapy in patients with diabetes mellitus

Czech version

Authors: Matej Samoš ¹; Tomáš Bolek ¹; Rid Škorňová ²; Ján Staško ²; Peter Galajda ¹; Marián Mokáň ¹
Authors‘ workplace: I. interná klinika Jesseniovej LF UK a UNM, Martin ¹; Národné centrum trombózy a hemostázy, Klinika hematológie a transfuziológie Jesseniovej LF UK, Martin ²
Published in: Forum Diab 2019; 8(2): 128-132
Category: Review Article

Overview

Type 2 diabetes mellitus (T2DM) is an independent risk factor of coronary atherosclerosis, including acute coronary syndromes (ACS). Antiplatelet (antiaggregant) therapy forms currently the basis of pharmacological treatment of ACS, and also the basis of pharmacological prevention of future ischemic events in patients with stable coronary artery disease, including those undergoing elective percutaneous coronary interventions (PCI). However, there are several reports pointing on a possible failure of this therapy which could be directly associated with T2DM. In fact, these observations lead to the introduction of novel potent ADP receptor blockers which enriched the possibilities of antiplatelet therapies in patients with T2DM and ACS (prasugrel, ticagrelor and cangrelor); and also in those undergoing elective PCI (cangrelor). This paper summarizes the modern antiplatelet strategies in patients with T2DM.

Keywords:

acute coronary syndrome – percutaneous coronary intervention – type 2 diabetes mellitus

Sources

Samoš M, Fedor M, Kovář F et al. Type 2 Diabetes and ADP Receptor Blocker Therapy. J Diabetes Res 2016; 2016: 6760710. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/6760710>.
Erlinge D, Varenhorst C, Braun OO et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52(24): 1968–1977. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.07.068>.
Angiolillo DJ, Capranzano P, Desai B et al. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 2009; 124(3): 318–322. Dostupné z DOI: <http://dx.doi.org/10.1016/j.thromres.2008.10.001>.
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54(8): 2430–2435.
Eskandarian R, Razavi M, Fattah A, Ghods K, Forozeshfard M. Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study. Int J Clin Pharmacol Ther 2017; 55(6): 493–497. Dostupné z DOI: <http://dx.doi.org/10.5414/CP202637>.
Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci 2014; 119(1): 25–31. Dostupné z DOI: <http://dx.doi.org/10.3109/03009734.2013.861549>.
Kapłon-Cieślicka A, Rosiak M, Postuła M, Serafin A, Kondracka A, Opolski G, Filipiak KJ. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol 2013; 71(9): 893–902. Dostupné z DOI: <http://dx.doi.org/10.5603/KP.2013.0055>.
Larsen SB, Grove EL, Neergaard-Petersen S et al. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. J Am Heart Assoc 2017; 6(8): pii: e006050. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.117.006050>.
Bethel MA, Harrison P, Sourij H et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Diabet Med 2016; 33(2): 224–230. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12828>.
Bowman L, Mafham M, Wallendszus K et al. [ASCEND Study Collaborative Group]. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379(16): 1529–1539. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1804988>.
Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34(39): 3035–3087. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht108>.
Samoš M, Šimonová R, Kovář F, Duraj L et al. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. Am J Emerg Med 2014; 32(5): 461–465. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajem.2014.01.006>.
Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39(3): 213–260. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx419>.
Wiviott SD, Braunwald E, McCabe CH et al. [TRITON-TIMI 38 Investigators]. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001–2015. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0706482>.
Samoš M, Fedor M, Kovář F et al. Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? Blood Coagul Fibrinolysis 2016; 27(2): 117–120. Dostupné z DOI: <http://dx.doi.org/10.1097/MBC.0000000000000406>.
Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045–1057. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0904327>.
Franchi F, Rollini F, Aggarwal N et al. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Circulation 2016; 134(11): 780–792. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.023402>.
Tan Q, Jiang X, Huang S et al. The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis. PLoS One 2017; 12(5): e0177872. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0177872>.
Bhatt DL, Stone GW, Mahaffey KW et al. [CHAMPION PHOENIX Investigators]. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368(14): 1303–1313. Dostupné z DOI: <http:///dx.doi.org/10.1056/NEJMoa1300815>.
Lu H, Guan W, Zhou Y et al. Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. Diabetes Ther 2019; Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–019–0593–7>
Samoš M, Bolek T, Kovář F et al. Diabetes mellitus a rezistencia na liečbu antagonistami ADP receptorov: význam, možnosti detekcie a terapeutického ovplyvnenia. AtheroRev 2018; 3(1): 34–39.